Esophageal cancer clinical trial landscape — the active clinical investigation of novel immunotherapy combinations, targeted therapies, neoadjuvant regimens, and biomarker-driven treatments — creates the research investment dimension, with the US Esophageal Cancer Market reflecting clinical trial activity as an important market development driver.

CheckMate 648 versus KEYNOTE-590 head-to-head landscape — the two competing IO approvals in esophageal cancer creating the clinical question of nivolumab plus ipilimumab (dual IO) versus pembrolizumab plus chemotherapy for ESCC — driving the ongoing comparative effectiveness investigation. The different mechanisms (anti-PD-1 + anti-CTLA-4 versus anti-PD-1 + chemotherapy) representing distinct biological treatment paradigms without direct head-to-head comparison.

FLOT chemotherapy expansion — the FLOT4 docetaxel/oxaliplatin/leucovorin/5-FU perioperative chemotherapy regimen's growing adoption in resectable EAC/GEJ cancer following the German AIO FLOT4 trial demonstrating superiority to ECF — creating the chemotherapy regimen evolution. The FLOT combination becoming preferred by many US oncologists for fit patients with resectable EAC.

Liquid biopsy research — the circulating tumor DNA (ctDNA) monitoring for esophageal cancer treatment response assessment, surveillance for recurrence, and residual disease detection after neoadjuvant therapy — representing the translational research commercialization pathway. The Guardant360 and Foundation Medicine ctDNA programs demonstrating commercial liquid biopsy applications in esophageal cancer management.

Do you think perioperative immunotherapy plus chemotherapy (FLOT + pembrolizumab) will replace the CROSS neoadjuvant chemoradiation standard for resectable esophageal cancer from the ongoing clinical trials?

FAQ

What are the most important ongoing clinical trials in esophageal cancer? Key esophageal cancer trials: KEYNOTE-585 (perioperative pembrolizumab + FLOT for EAC/GEJ — OS results pending); CheckMate 577 (nivolumab adjuvant after R0 resection + neoadjuvant chemoRT — FDA approved 2021); ATTRACTION-3 (nivolumab second-line ESCC — established); DESTINY-Gastric04 (T-DXd first-line HER2+ gastric/GEJ — ongoing); NivoNeo (nivolumab + CROSS neoadjuvant for resectable ESCC); MOONLIGHT (EU platform trial esophageal); targeted therapy trials: claudin 18.2 (zolbetuximab), FGFR2b (bemarituzumab).

What is CheckMate 577 and what did it establish? CheckMate 577 (BMS): nivolumab adjuvant after R0 esophageal/GEJ resection following neoadjuvant chemoradiation (CROSS protocol) in patients with residual pathological disease (non-pathological complete response); design: nivolumab twelve months versus placebo; results: DFS 22.4 months nivolumab versus 11.0 months placebo (HR 0.69); OS trend positive; FDA approved August 2021; significance: first adjuvant treatment approved for esophageal cancer; targets: patients with residual disease after neoadjuvant chemoRT (majority — only approximately twenty-nine percent achieve pCR with CROSS); commercial: significant patient population eligible; standard of care at major centers.

#USEsophagealCancer #EsophagealTrials #CheckMate577 #EsophagealImmunotherapy #KEYNOTE585 #EsophagealResearch